{"id":71456,"date":"2026-05-20T12:05:00","date_gmt":"2026-05-20T12:05:00","guid":{"rendered":"https:\/\/medsbase.com\/adipotide-ftpp\/"},"modified":"2026-05-21T07:14:08","modified_gmt":"2026-05-21T07:14:08","slug":"adipotide-ftpp","status":"publish","type":"product","link":"https:\/\/medsbase.com\/cs\/product\/adipotide-ftpp\/","title":{"rendered":"Adipotid (FTPP \u2014 tukov\u011b c\u00edlen\u00fd proapoptotick\u00fd peptid)"},"content":{"rendered":"

<\/p>\n

\n

Rychl\u00e1 odpov\u011b\u010f \u2014 Co je Adipotide (FTPP)?<\/h3>\n

Adipotide<\/strong> (tak\u00e9 naz\u00fdvan\u00fd FTPP<\/strong> \u2014 \u201cFat-Targeted Pro-apoptotic Peptide\u201d) je syntetick\u00fd 25-aminokyselinov\u00fd chim\u00e9rick\u00fd v\u00fdzkumn\u00fd peptid vyvinut\u00fd Koloninem, Arapem a Pasqualinim<\/strong> v MD Anderson Cancer Center. Spojuje dv\u011b funk\u010dn\u011b odli\u0161n\u00e9 dom\u00e9ny: cyklick\u00fd nav\u00e1d\u011bc\u00ed peptid CKGGRAKDC<\/strong> kter\u00fd se v\u00e1\u017ee na prohibitin-1 (a annexin A2) na endotelu kapil\u00e1r b\u00edl\u00e9 tukov\u00e9 tk\u00e1n\u011b, a D-stereoizomern\u00ed pro-apoptotick\u00fd \u03b1-helik\u00e1ln\u00ed peptid D(KLAKLAK)2<\/sub><\/strong> kter\u00fd naru\u0161uje mitochondri\u00e1ln\u00ed membr\u00e1ny. F\u00fazovan\u00e1 chim\u00e9ra selektivn\u011b c\u00edl\u00ed na vaskulaturu z\u00e1sobuj\u00edc\u00ed b\u00edlou tukovou tk\u00e1\u0148 a spou\u0161t\u00ed apopt\u00f3zu endotelu, \u010d\u00edm\u017e zbavuje adipocyty krevn\u00edho z\u00e1soben\u00ed a zp\u016fsobuje rychl\u00fd \u00fabytek tukov\u00e9 tk\u00e1n\u011b. Publikov\u00e1no u ob\u00e9zn\u00edch makak\u016f rhesus (Barnhart et al. 2011, Science Translational Medicine<\/em>) \u2014 ~11% \u00fabytek t\u011blesn\u00e9 hmotnosti za 4 t\u00fddny. Upozorn\u011bn\u00ed:<\/strong> zdokumentovan\u00e1 nefrotoxicita v prim\u00e1t\u00edch studi\u00edch je hlavn\u00edm p\u0159ek\u00e1\u017ekou pro klinick\u00e9 vyu\u017eit\u00ed, a f\u00e1ze I klinick\u00e9ho testov\u00e1n\u00ed u lid\u00ed (2014\u20132016) m\u011bla omezen\u00e9 publikovan\u00e9 v\u00fdsledky. Pouze pro laboratorn\u00ed v\u00fdzkum.<\/p>\n<\/div>\n

Co z\u00edsk\u00e1te s MedsBase:<\/strong> Lyofilizovan\u00fd pr\u00e1\u0161ek \u226599% HPLC-verifikovan\u00fd \u00b7 COA dostupn\u00fd na vy\u017e\u00e1d\u00e1n\u00ed \u00b7 Diskr\u00e9tn\u00ed teplotn\u011b stabiln\u00ed balen\u00ed \u00b7 Celosv\u011btov\u00e1 dod\u00e1vka v\u00fdzkumn\u00fdch materi\u00e1l\u016f \u00b7 1,400+ ov\u011b\u0159en\u00fdch recenz\u00ed z\u00e1kazn\u00edk\u016f<\/a><\/div>\n

\ud83d\udce6 Ka\u017ed\u00e1 objedn\u00e1vka je pokryta na\u0161\u00ed Z\u00e1rukou op\u011btovn\u00e9ho odesl\u00e1n\u00ed<\/strong><\/a> \u2014 pokud va\u0161e z\u00e1silka nedoraz\u00ed do 20 pracovn\u00edch dn\u016f, p\u0159epos\u00edl\u00e1me ji.<\/p>\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
Specifikace<\/th>\nDetail<\/th>\n<\/tr>\n<\/thead>\n
T\u0159\u00edda slou\u010denin<\/strong><\/td>\nSyntetick\u00fd 25-aminokyselinov\u00fd chim\u00e9rick\u00fd peptidomimetikum; nav\u00e1d\u011bc\u00ed dom\u00e9na + pro-apoptotick\u00e1 dom\u00e9na spojen\u00e1 GG linkerem; pro-apoptotick\u00fd peptid c\u00edlen\u00fd na tukov\u00e9 tk\u00e1n\u011b<\/em><\/td>\n<\/tr>\n
Chemick\u00fd n\u00e1zev<\/strong><\/td>\nAdipotide \/ FTPP (Fat-Targeted Pro-apoptotic Peptide); synonyma: Prohibitin-targeting peptide-1 + D(KLAKLAK)2<\/sub> chim\u00e9ra; CKGGRAKDC-GG-D(KLAKLAK)2<\/sub><\/td>\n<\/tr>\n
CAS \u010d\u00edslo<\/strong><\/td>\nV\u00fdzkumn\u00fd chim\u00e9rick\u00fd peptid \u2014 \u017e\u00e1dn\u00e9 jednozna\u010dn\u00e9 CAS \u010d\u00edslo. N\u011bkter\u00e9 dodavatelsk\u00e9 seznamy uv\u00e1d\u011bj\u00ed 1422956-49-3; identifikace prim\u00e1rn\u011b podle publikovan\u00e9 sekvence (CKGGRAKDC-GG-D(KLAKLAK)2<\/sub>) sp\u00ed\u0161e ne\u017e podle CAS. Pro identifikaci specifickou pro \u0161ar\u017ei konzultujte COA.<\/td>\n<\/tr>\n
item9<\/strong><\/td>\nCys-Lys-Gly-Gly-Arg-Ala-Lys-Asp-Cys (cyklovan\u00fd Cys1\u2013Cys9 disulfid, \u201cCKGGRAKDC\u201d prohibitin-v\u00e1zaj\u00edc\u00ed nav\u00e1d\u011bc\u00ed motiv) \u2014 Gly-Gly linker \u2014 D-Lys-D-Leu-D-Ala-D-Lys-D-Leu-D-Ala-D-Lys-D-Lys-D-Leu-D-Ala-D-Lys-D-Leu-D-Ala-D-Lys (D-stereoizomern\u00ed pro-apoptotick\u00fd \u03b1-helik\u00e1ln\u00ed peptid D(KLAKLAK)2<\/sub>). Celkov\u00e1 d\u00e9lka: 25 aminokyselinov\u00fdch zbytk\u016f (9 + 2 + 14).<\/td>\n<\/tr>\n
item7<\/strong><\/td>\n~2 611 Da (vypo\u010dten\u00fd pr\u016fm\u011br; uv\u00e1d\u011bno jako 2 500\u20132 611 Da v publikovan\u00fdch zdroj\u00edch)<\/td>\n<\/tr>\n
item2<\/strong><\/td>\nChim\u00e9rick\u00fd peptid \u2014 sekvence CKGGRAKDC-GG-D(KLAKLAK)2<\/sub>; p\u0159ibli\u017en\u00e1 molekulov\u00e1 hmotnost (MF) odvozen\u00e1 ze sekvence ~C114<\/sub>H196<\/sub>N40<\/sub>O26<\/sub>S2<\/sub>; publikovan\u00e1 molekulov\u00e1 hmotnost (MW) ~2 611 Da (cyklick\u00e1 disulfidov\u00e1 forma). \u017d\u00e1dn\u00e9 jednozna\u010dn\u00e9 Sigma-kanonick\u00e9 CAS; identifikace sekvenc\u00ed + COA.<\/td>\n<\/tr>\n
Mechanismus \u00fa\u010dinku<\/strong><\/td>\nDvouf\u00e1zov\u011b c\u00edlen\u00e1 apopt\u00f3za<\/strong>. (1) Cyklick\u00e1 dom\u00e9na CKGGRAKDC se v\u00e1\u017ee na prohibitin-1 \u2014 mitochondri\u00e1ln\u00ed chaperonov\u011b podobn\u00fd protein, kter\u00fd je neobvykle exprimov\u00e1n na povrchu<\/em> kapil\u00e1rn\u00edch endoteli\u00e1ln\u00edch bun\u011bk z\u00e1sobuj\u00edc\u00edch b\u00edlou tukovou tk\u00e1\u0148 (identifikov\u00e1no Koloninem et al. 2004 in-vivo f\u00e1govou displayovou screeningovou metodou) \u2014 a tak\u00e9 na annexin A2 ve stejn\u00e9 vaskulatu\u0159e. (2) Po nav\u00e1z\u00e1n\u00ed na bun\u011b\u010dn\u00fd povrch je chim\u00e9ra internalizov\u00e1na a pro-apoptotick\u00e1 dom\u00e9na D(KLAKLAK)2<\/sub> s \u03b1-helik\u00e1ln\u00ed strukturou naru\u0161uje mitochondri\u00e1ln\u00ed membr\u00e1nu endoteli\u00e1ln\u00edch bun\u011bk p\u0159\u00edmou interakc\u00ed s membr\u00e1nou. Kolaps mitochondri\u00ed \u2192 kasp\u00e1zou zprost\u0159edkovan\u00e1 apopt\u00f3za tukov\u00e9 vaskulatury \u2192 omezen\u00ed krevn\u00edho z\u00e1soben\u00ed adipocyt\u016f \u2192 \u00fabytek hmoty tukov\u00e9 tk\u00e1n\u011b v pr\u016fb\u011bhu dn\u016f a\u017e t\u00fddn\u016f.<\/td>\n<\/tr>\n
D-aminokyselinov\u00e1 stereochemie<\/strong><\/td>\nPro-apoptotick\u00e1 dom\u00e9na KLAKLAKKLAKLAK je syntetizov\u00e1na v\u00fdhradn\u011b v D-aminokyselinov\u00e9 stereochemii<\/strong> (zrcadlov\u00e9 uspo\u0159\u00e1d\u00e1n\u00ed zbytk\u016f). D-stereochemie zaji\u0161\u0165uje odolnost v\u016f\u010di prote\u00e1z\u00e1m \u2014 hostitelsk\u00e9 prote\u00e1zy rozpozn\u00e1vaj\u00ed pouze L-aminokyseliny \u2014 co\u017e prodlu\u017euje polo\u010das killer dom\u00e9ny in-vivo oproti p\u0159irozen\u00e9 L-form\u011b. Dom\u00e9na pro nav\u00e1d\u011bn\u00ed (CKGGRAKDC) je v norm\u00e1ln\u00ed L-aminokyselinov\u00e9 stereochemii, proto\u017ee se mus\u00ed v\u00e1zat na hostitelsk\u00fd protein (prohibitin-1) v kanonick\u00e9 receptor-ligandov\u00e9 geometrii.<\/td>\n<\/tr>\n
Dokumentovan\u00e1 toxicita (relevantn\u00ed pro v\u00fdzkum)<\/strong><\/td>\nNefrotoxicita<\/strong> byla zdokumentov\u00e1na ve studii na ob\u00e9zn\u00edch opic\u00edch druhu makak rhesus (Barnhart et al. 2011) a p\u0159edstavuje hlavn\u00ed p\u0159ek\u00e1\u017eku pro translaci do praxe. Ledviny exprimuj\u00ed prohibitin a jsou vysoce vaskularizovan\u00e9, proto mimoc\u00edlen\u00e9 nav\u00e1d\u011bn\u00ed chim\u00e9ry na ren\u00e1ln\u00ed vaskulaturu zp\u016fsobuje d\u00e1vkov\u011b z\u00e1visl\u00e9 po\u0161kozen\u00ed ledvin. Skupina MD Anderson p\u0159eorientovala pou\u017eit\u00ed slou\u010deniny sp\u00ed\u0161e na l\u00e9\u010dbu rakoviny ne\u017e obezity pr\u00e1v\u011b proto, \u017ee pom\u011br rizika a p\u0159\u00ednosu je p\u0159\u00edzniv\u011bj\u0161\u00ed v kontextu l\u00e9\u010dby rakoviny ne\u017e v kontextu elektivn\u00edho \u00fabytku tuku. V\u00fdzkumn\u00edci v jak\u00e9mkoli in-vivo protokolu s Adipotidem by m\u011bli zahrnout komplexn\u00ed monitorov\u00e1n\u00ed ren\u00e1ln\u00edch funkc\u00ed (mo\u010dovina, kreatinin, vy\u0161et\u0159en\u00ed mo\u010di).<\/td>\n<\/tr>\n
item11<\/strong><\/td>\nLyofilizovan\u00fd b\u00edl\u00fd a\u017e sv\u011btle \u017elut\u00fd amorfn\u00ed pr\u00e1\u0161ek; jednor\u00e1zov\u00e9 v\u00fdzkumn\u00e9 lahvi\u010dky. Synt\u00e9za je technicky n\u00e1ro\u010dn\u00e1 (Fmoc-SPPS s D-aminokyselinami + cyklick\u00e9 uzav\u0159en\u00ed disulfidov\u00e9 vazby u nav\u00e1d\u011bc\u00ed dom\u00e9ny) \u2014 stupe\u0148 \u010distoty je u t\u00e9to slou\u010deniny d\u016fle\u017eit\u011bj\u0161\u00ed ne\u017e u v\u011bt\u0161iny ostatn\u00edch.<\/td>\n<\/tr>\n
item13<\/strong><\/td>\n\u226599% (HPLC ov\u011b\u0159en\u00e9); MALDI-TOF hmotnostn\u00ed spektrometrie potvrzuje ~2,611 Da. Tvorba disulfidov\u00fdch m\u016fstk\u016f cyklick\u00e9 dom\u00e9ny potvrzena redukovanou vs. neredukovanou hmotnostn\u00ed spektrometri\u00ed. COA dostupn\u00e9 na vy\u017e\u00e1d\u00e1n\u00ed.<\/td>\n<\/tr>\n
Rozpustnost<\/strong><\/td>\nRozpustn\u00e9 v bakteriostatick\u00e9 vod\u011b, steriln\u00ed vod\u011b a PBS p\u0159i \u22652 mg\/ml; rozpustn\u00e9 v DMSO p\u0159i \u226510 mg\/ml pro p\u0159\u00edpravu pracovn\u00edho z\u00e1sobn\u00edku in vitro.2<\/sub> Dom\u00e9na m\u00e1 vlastnosti podobn\u00e9 surfaktant\u016fm \u2014 roztoky mohou p\u0159i po\u010d\u00e1te\u010dn\u00ed rekonstituci p\u0159echodn\u011b p\u011bnit; p\u0159ed odb\u011brem je nechte usadit.<\/td>\n<\/tr>\n
Skladov\u00e1n\u00ed<\/strong><\/td>\nPro laboratorn\u00ed v\u00fdzkum pouze. Nepou\u017e\u00edvat pro hum\u00e1nn\u00ed nebo veterin\u00e1rn\u00ed diagnostick\u00e9 nebo terapeutick\u00e9 \u00fa\u010dely. Adipotide nen\u00ed na sou\u010dasn\u00e9m seznamu zak\u00e1zan\u00fdch l\u00e1tek WADA pod jeho specifick\u00fdm n\u00e1zvem (jeho v\u00fdvojov\u00fd oblouk sm\u011b\u0159oval sp\u00ed\u0161e k onkologii ne\u017e k vyu\u017eit\u00ed ve sportovn\u00edm v\u00fdkonu).<\/td>\n<\/tr>\n
Pouze pro v\u00fdzkum<\/strong><\/td>\nLyofilizovan\u00e9: 2\u20138 \u00b0C neotev\u0159en\u00e9 pro kr\u00e1tkodob\u00fd pracovn\u00ed z\u00e1sobn\u00edk; \u221220 \u00b0C pro dlouhodob\u00e9 skladov\u00e1n\u00ed (stabiln\u00ed \u226536 m\u011bs\u00edc\u016f p\u0159i \u221220 \u00b0C). Chra\u0148te p\u0159ed sv\u011btlem. Vyvarujte se opakovan\u00fdm cykl\u016fm mrazu\u2013t\u00e1n\u00ed \u2014 kumulativn\u00ed cykly riskuj\u00ed disulfidov\u00e9 m\u016fstky Cys1\u2013Cys9.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

<\/p>\n

Pro laboratorn\u00ed v\u00fdzkum pouze. Nepou\u017e\u00edvat pro hum\u00e1nn\u00ed nebo veterin\u00e1rn\u00ed diagnostick\u00e9 nebo terapeutick\u00e9 \u00fa\u010dely. Adipotide nen\u00ed na sou\u010dasn\u00e9m seznamu zak\u00e1zan\u00fdch l\u00e1tek WADA pod jeho specifick\u00fdm n\u00e1zvem.<\/h2>\n

Adipotide<\/strong> (tak\u00e9 naz\u00fdvan\u00fd FTPP<\/strong> \u2014 \u201cFat-Targeted Pro-apoptotic Peptide\u201d) je syntetick\u00e9 25-aminokyselinov\u00e9 chim\u00e9rick\u00e9 peptidomimetikum vyvinut\u00e9 v \u2014 \u201ePeptid c\u00edlen\u00fd na tuk\u201c) je syntetick\u00fd 25-aminokyselinov\u00fd chim\u00e9rick\u00fd peptidomimetick\u00fd vyvinut\u00fd v<\/strong> od Mikhail Kolonin, Wadih Arap, a Renata Pasqualini. Slou\u010denina p\u0159edstavuje jeden z nej\u010dist\u0161\u00edch p\u0159\u00edklad\u016f racion\u00e1ln\u00ed n\u00e1vrh chim\u00e9rn\u00edch peptidov\u00fdch l\u00e9\u010div<\/strong> v modern\u00ed peptidov\u00e9 farmakologii: tk\u00e1\u0148ov\u011b specifick\u00e1 nav\u00e1d\u011bc\u00ed dom\u00e9na (identifikovan\u00e1 in-vivo f\u00e1gov\u00fdm displejem) je kovalentn\u011b f\u00fazov\u00e1na s generickou usmrcuj\u00edc\u00ed dom\u00e9nou (proapoptotick\u00fd mitochondrie-naru\u0161uj\u00edc\u00ed \u03b1-helik\u00e1ln\u00ed peptid), \u010d\u00edm\u017e vznik\u00e1 chim\u00e9ra, kter\u00e1 selektivn\u011b dopravuje usmrcuj\u00edc\u00ed aktivitu do c\u00edlov\u00e9 tk\u00e1n\u011b.<\/p>\n

Dv\u011b funk\u010dn\u00ed dom\u00e9ny a logika jejich n\u00e1vrhu:<\/p>\n

Dv\u011b funk\u010dn\u00ed dom\u00e9ny a logika n\u00e1vrhu:.<\/strong> Kolonin et\u00a0al. (2004) pou\u017eili in-vivo screening f\u00e1gov\u00fdch displej\u016f u ob\u00e9zn\u00edch my\u0161\u00ed k identifikaci 9-zbytkov\u00e9ho cyklick\u00e9ho peptidu (sekvence Cys-Lys-Gly-Gly-Arg-Ala-Lys-Asp-Cys, s disulfidov\u00fdm m\u016fstkem Cys1-Cys9, kter\u00fd omezuje geometrii), kter\u00fd se selektivn\u011b v\u00e1\u017ee na vaskulaturu b\u00edl\u00e9 tukov\u00e9 tk\u00e1n\u011b. Vazebn\u00fd c\u00edl byl n\u00e1sledn\u011b identifikov\u00e1n jako Kolonin et al. (2004) pou\u017eili in-vivo f\u00e1govou displayovou screeningovou metodu u ob\u00e9zn\u00edch my\u0161\u00ed k identifikaci 9-residu\u00e1ln\u00edho cyklick\u00e9ho peptidu (sekvence Cys-Lys-Gly-Gly-Arg-Ala-Lys-Asp-Cys, s m\u016fstkem Cys1-Cys9, kter\u00fd omezuje geometrii), kter\u00fd selektivn\u011b v\u00e1\u017ee c\u00e9vn\u00ed \u0159e\u010d b\u00edl\u00e9 tukov\u00e9 tk\u00e1n\u011b. C\u00edl vazby byl n\u00e1sledn\u011b identifikov\u00e1n jako<\/strong> (PHB1) \u2014 chaperonov\u011b podobn\u00fd protein, kter\u00fd se norm\u00e1ln\u011b vyskytuje na mitochondri\u00e1ln\u00ed membr\u00e1n\u011b, ale v endotelu b\u00edl\u00e9 tukov\u00e9 tk\u00e1n\u011b je tak\u00e9 exprimov\u00e1n na bun\u011b\u010dn\u00e9m povrchu a dostupn\u00fd pro cirkuluj\u00edc\u00ed ligandy. Annexin A2 byl identifikov\u00e1n jako sekund\u00e1rn\u00ed vazebn\u00fd partner ve stejn\u00e9 vaskulatu\u0159e. Dom\u00e9na CKGGRAKDC funguje jako molekul\u00e1rn\u00ed \u201epsac\u00ed \u010d\u00edslo\u201c, kter\u00e9 nasm\u011bruje chim\u00e9ru specificky na kapil\u00e1ry tukov\u00e9 tk\u00e1n\u011b nam\u00edsto obecn\u00e9ho syst\u00e9mov\u00e9ho endotelu.<\/p>\n

2. D(KLAKLAK)2<\/sub> \u2014 pro-apoptotick\u00fd \u03b1-helik\u00e1ln\u00ed zab\u00edjej\u00edc\u00ed peptid.<\/strong> 14-aminokyselinov\u00fd D-aminokyselinov\u00fd \u03b1-helik\u00e1ln\u00ed peptid D-Lys-D-Leu-D-Ala-D-Lys-D-Leu-D-Ala-D-Lys-D-Lys-D-Leu-D-Ala-D-Lys-D-Leu-D-Ala-D-Lys je syntetick\u00fd membr\u00e1nov\u011b disruptivn\u00ed peptid (p\u016fvodn\u011b vyvinut\u00fd pro v\u00fdzkum c\u00edlen\u00ed na rakovinu Ellerby et al. 1999). Amfipatick\u00e1 \u03b1-helik\u00e1ln\u00ed geometrie zp\u016fsobuje, \u017ee se peptid vkl\u00e1d\u00e1 do membr\u00e1n; D-aminokyselinov\u00e1 stereochemie zaji\u0161\u0165uje odolnost v\u016f\u010di prote\u00e1z\u00e1m in vivo. Kl\u00ed\u010dov\u00e9 je, \u017ee zab\u00edjej\u00edc\u00ed aktivita je ne<\/em> selektivn\u00ed pro jak\u00fdkoli konkr\u00e9tn\u00ed bun\u011b\u010dn\u00fd typ \u2014 peptid naru\u0161\u00ed mitochondri\u00e1ln\u00ed membr\u00e1ny v podstat\u011b v jak\u00e9koli bu\u0148ce, do kter\u00e9 se dostane \u2014 co\u017e je d\u016fvod, pro\u010d je nutn\u00e9 jej sp\u00e1rovat s nav\u00e1d\u011bc\u00ed dom\u00e9nou pro terapeutick\u00e9 vyu\u017eit\u00ed.<\/p>\n

3. GG spojka.<\/strong> Dv\u011b funk\u010dn\u00ed dom\u00e9ny jsou spojeny jednoduchou di-glycinovou spojkou, kter\u00e1 poskytuje flexibiln\u00ed rozestup a zabra\u0148uje sterick\u00e9mu ru\u0161en\u00ed mezi nav\u00e1d\u011bc\u00ed a zab\u00edjej\u00edc\u00ed funkc\u00ed.<\/p>\n

Kombinovan\u00e1 chim\u00e9ra (CKGGRAKDC-GG-D(KLAKLAK)2<\/sub>, ~2 611 Da) byla charakterizov\u00e1na u ob\u00e9zn\u00edch makak\u016f v pr\u016flomov\u00e9 studii Barnhart et al. (2011) publikovan\u00e9 v Science Translational Medicine<\/em> \u2014 zv\u00ed\u0159ata ztratila p\u0159ibli\u017en\u011b 11 % t\u011blesn\u00e9 hmotnosti b\u011bhem 4 t\u00fddn\u016f denn\u00edho subkut\u00e1nn\u00edho pod\u00e1v\u00e1n\u00ed, se sou\u010dasn\u00fdm zlep\u0161en\u00edm citlivosti na inzul\u00edn. Nicm\u00e9n\u011b stejn\u00e1 studie a n\u00e1sledn\u00e9 pr\u00e1ce dokumentovaly d\u00e1vkov\u011b z\u00e1visl\u00e1 nefrotoxicita<\/strong>: ledviny maj\u00ed vysokou expresi prohibitu a jsou hust\u011b vaskularizovan\u00e9, proto mimoc\u00edlen\u00e9 nav\u00e1d\u011bn\u00ed chim\u00e9ry na ren\u00e1ln\u00ed vaskulaturu zp\u016fsobuje po\u0161kozen\u00ed tubul\u016f v ren\u00e1ln\u00ed k\u016f\u0159e. Skupina MD Anderson p\u0159eorientovala Adipotide pro hum\u00e1nn\u00ed onkologii nam\u00edsto obezity a v letech 2014\u20132016 provedla klinickou studii f\u00e1ze I u pacient\u016f s metastatick\u00fdm karcinomem prostaty s omezen\u00fdmi publikovan\u00fdmi v\u00fdsledky. Slou\u010denina z\u016fst\u00e1v\u00e1 dodnes v\u00fdzkumn\u00fdm n\u00e1strojem \u2014 je \u010dasto citov\u00e1na jako referen\u010dn\u00ed p\u0159\u00edklad designu chim\u00e9rick\u00fdch peptidov\u00fdch l\u00e9\u010div a kanonick\u00fd farmakologick\u00fd n\u00e1stroj pro studium c\u00edlen\u00e9 apopt\u00f3zy tukov\u00e9 vaskulatury.<\/p>\n

Mechanismus \u00fa\u010dinku \u2014 tk\u00e1\u0148ov\u011b c\u00edlen\u00e1 apopt\u00f3za tukov\u00e9 vaskulatury<\/h2>\n

Mechanismus \u00fa\u010dinku Adipotidu pat\u0159\u00ed k nejl\u00e9pe charakterizovan\u00fdm ve farmakologii chim\u00e9rick\u00fdch peptid\u016f:<\/p>\n